Prasugrel Discontinuation Before Elective Surgery
Discontinue prasugrel 7 days prior to elective surgery. This is the clear recommendation from both the most recent American College of Chest Physicians (ACCP) 2022 guidelines and the FDA drug label 1, 2.
Primary Recommendation
The 2022 ACCP guidelines explicitly state for pre-operative P2Y12 inhibitor interruption: 7 days for prasugrel 1. This aligns perfectly with the FDA boxed warning, which states: "When possible, discontinue prasugrel at least 7 days prior to any surgery" 2.
Context-Specific Considerations
For CABG Surgery
The same 7-day discontinuation window applies specifically to CABG procedures. The ACCP guidelines recommend interrupting P2Y12 inhibitors (including prasugrel) perioperatively for CABG, with the implementation note specifying 7 days for prasugrel 1.
For Patients With Recent Coronary Stents (6-12 weeks)
If your patient has had a coronary stent placed within the last 6-12 weeks, you face a critical decision point. The ACCP guidelines suggest either:
- Continue both antiplatelet agents through surgery, OR
- Stop one antiplatelet agent within 7-10 days of surgery 1
This decision hinges on:
- Timing of stent placement (closer to 6 vs. 12 weeks)
- Type of stent (drug-eluting vs. bare-metal)
- Stent location (dominant coronary artery or not)
- Surgery bleeding risk vs. risk of acute coronary syndrome/stent thrombosis
The Canadian guidelines emphasize a "heart team approach" for these complex decisions 3.
Comparison to Other P2Y12 Inhibitors
For context, prasugrel requires the longest discontinuation period among P2Y12 inhibitors:
This longer window reflects prasugrel's more potent and sustained platelet inhibition compared to other agents.
Critical Pitfalls to Avoid
Do not start prasugrel in patients likely to undergo urgent CABG 2. This is part of the FDA boxed warning and reflects the significant bleeding risk.
Do not routinely use platelet function testing to guide timing of surgery. The ACCP guidelines recommend against routine platelet function testing prior to surgery, though it could be considered in specific scenarios like CABG in patients who recently started a P2Y12 inhibitor 1.
Do not abruptly discontinue without considering thrombotic risk. The FDA label warns that stopping prasugrel increases the risk of subsequent cardiovascular events 2. Balance this against surgical bleeding risk on a case-by-case basis, particularly in patients with recent stents.
Post-Operative Resumption
Resume prasugrel within 24 hours after surgery when hemostasis is adequate 1. This applies to both general surgery and CABG procedures, though resumption may need to be delayed if post-CABG thrombocytopenia develops (platelet count <50,000/μL) 1.
Special Populations
For patients <60 kg body weight or ≥75 years of age, prasugrel carries additional bleeding risk per the FDA boxed warning 2. The 7-day discontinuation window remains the same, but heightened vigilance for bleeding complications is warranted.